---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-046955"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:43:14.713389+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apogee reports Q1 net loss $55.3M; positive APG808 Phase 1b data with 53% FeNO suppression

## Summary
- Q1 net loss $55.3M vs $32.1M YoY; cash $681.4M supports runway into Q1 2028.
- Positive interim Phase 1b APG808 results: FeNO suppression 53% max, sustained 50% at 12 weeks; well tolerated.
- Phase 2 APEX trial of APG777 advancing; interim Part A 16-week data expected mid-2025.
- First patient dosed in Phase 1b APG777 asthma trial; readout expected 1H 2026.
- APG279 (APG777+APG990) head-to-head vs DUPIXENT on track to initiate in 2025; readout 2H 2026.

## SEC filing metadata
- accession: 0001104659-25-046955
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465925046955/0001104659-25-046955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465925046955/tm2514695d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-046955
- JSON: https://secwatch.observer/filing/0001104659-25-046955.json
- Plain text: https://secwatch.observer/filing/0001104659-25-046955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.